1-20 of 20
Keywords: Ipilimumab
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Case Rep Oncol (2023) 16 (1): 81–87.
Published Online: 17 February 2023
... on the parietal pleura whose pathological analysis indicated PPA. The patient received immunotherapy combined with nivolumab and ipilimumab. A cycle of nivolumab and ipilimumab improved his hemorrhagic anemia and reduced the pleural effusion and tumor size. This treatment outcome suggests that nivolumab...
Journal Articles
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2022) 14 (3): 1289–1294.
Published Online: 14 September 2021
... or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2020) 13 (2): 621–626.
Published Online: 09 June 2020
.... Ipilimumab Nivolumab Primary adrenal insufficiency Immune-related adverse events Immune checkpoint inhibitors (ICI) have improved the prognosis of several solid tumor types, including melanoma, renal cell carcinoma (RCC), non-small cell lung cancer, and urothelial carcinoma, among others. Some...
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2020) 13 (2): 550–557.
Published Online: 19 May 2020
... describe 2 female patients: an 81-year-old treated with pembrolizumab and a 55-year-old treated with a combination of nivolumab and ipilimumab. Both patients underwent resection of metastases; while under treatment, both developed myocarditis, most probably as a toxicity from pembrolizumab and nivolumab...
Journal Articles
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2018) 11 (2): 549–556.
Published Online: 17 August 2018
...Yoshito Nishimura; Miho Yasuda; Kazuki Ocho; Masaya Iwamuro; Osamu Yamasaki; Takehiro Tanaka; Fumio Otsuka Immune checkpoint inhibitors such as ipilimumab, a cytotoxic T-lymphocyte-associated antigen-4 inhibitor, have been widely used for advanced malignancies. As these inhibitors improve antitumor...
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2018) 11 (2): 521–526.
Published Online: 27 July 2018
... to CNS involvement following dual checkpoint blockade with nivolumab and ipilimumab for metastatic melanoma and review the relevant literature. Approximately 10 months following treatment with ipilimumab/nivolumab, the patient was admitted to the hospital after developing 2 weeks of progressive...
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2018) 11 (1): 17–20.
Published Online: 04 January 2018
... with the combination of ipilimumab (CTLA4 antibody) and the programmed death (PD)-1 inhibitor nivolumab compared with monotherapy. Based on these results, the combination of nivolumab and ipilimumab has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma. So far, there have...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2017) 10 (2): 456–461.
Published Online: 23 May 2017
...Reem Akel; Bilal Anouti; Arafat Tfayli Background: Antitumor immunotherapy has become a major player in cancer therapy. Ipilimumab is a humanized monoclonal antibody against the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), an important downregulator of T-cell activation. Ipilimumab has...
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2017) 9 (3): 705–713.
Published Online: 08 November 2016
...Marcus Messmer; Sunita Upreti; Yaman Tarabishy; Nikhilesh Mazumder; Reezwana Chowdhury; Mark Yarchoan; Matthias Holdhoff Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma. It was the first...
Journal Articles
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2017) 9 (3): 543–546.
Published Online: 22 September 2016
... mutations. Herein, we describe two cases of patients with metastatic melanomas, each carrying a ‘nonstandard’ mutation in the BRAF gene: BRAF K601E and BRAF G466E , respectively. The first patient was treated with a MEK inhibitor and the second one with ipilimumab. However, not all BRAF mutations result...
Journal Articles
Subject Area:
Oncology
Case Rep Oncol (2013) 6 (2): 285–288.
Published Online: 30 May 2013
... mutation, and ipilimumab for unresectable or metastatic melanoma. Case Presentation: We present here the case of a 65-year-old Caucasian male diagnosed with advanced melanoma in April 2011 and treated with ipilimumab (Yervoy®), a monoclonal antibody targeting cytotoxic T-lymphocyte-associated antigen 4...
Journal Articles